medigraphic.com
Colegio de Medicina Interna de México.

2018, Número 6

<< Anterior Siguiente >>

Med Int Mex 2018; 34 (6)


Administración de omalizumab en pacientes mexicanos con diagnóstico de asma moderada a grave no atópica

Herrera-García JC, Galindo-Solano R, Arellano-Montellano EI, Jaramillo- Arellano LE, Espinosa-Arellano A

Idioma: Español
Referencias bibliográficas: 26
Paginas: 833-839
Archivo PDF: 463.27 Kb.


RESUMEN

Objetivo: Determinar la mejoría clínica en los pacientes con diagnóstico de asma moderada a severa no atópica en tratamiento con omalizumab.
Material y Método: estudio prospectivo y observacional en el que del 1 de enero de 2017 al 1 de enero de 2018 se incluyeron pacientes adultos que, a pesar del tratamiento diario con o sin mantenimiento con corticoesteroides orales, tenían asma moderada a severa no atópica descontrolada; los pacientes se asignaron a recibir omalizumab por concentraciones de IgE. El punto final primario fue el cambio en los parámetros clínicos y funcionales de los pacientes por medio de examen de la prueba ACT (Asthma Control Test).
Resultados: Se incluyeron 20 pacientes. Tras 52 semanas de administración de omalizumab los pacientes mostraron aumento moderado en el FEV1 y mejoría de los parámetros clínicos y funcionales. El alivio sintomático de los pacientes se consideró principalmente con el aumento en la prueba ACT de 10 a 20 puntos. También se observó buena tolerancia al medicamento, sin ningún efecto adverso grave y mejoría en la calidad de vida de los pacientes.
Conclusiones: Omalizumab tiene un papel terapéutico en el asma no atópica moderada a severa. Nuestros resultados apoyan la eficacia clínica de omalizumab en los pacientes asmáticos no atópicos mexicanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Borriello EM, Vatrella A. Does non-allergic asthma still exist? Shortness of Breath 2013;2(2):55-60.

  2. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97(1):75-85.

  3. Brown WG, Halonen MJ, Kaltenborn WT, Barbee RA. The relationship of respiratory allergic, skin test reactivity and serum IgE in a community population sample. J Allergy Clin Immunol 1979;63(5):328-335.

  4. Sunyer J, Antó JM, Castellsague J, Soriano JB, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. Eur Resp J Sep 1996;9(9):1880-1884.

  5. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated in non-allergic individuals. Eur Resp J Oct 2000;16(4):609-614.

  6. Domingo C. Overlapping effects of new monoclonal antibodies for severe asthma. In: Drugs. Springer International Publising AG; 2017. DOI: 10.1007/s40265-017-0810-5.

  7. Herrera-García JC, Sánchez-Casas GA, Arellano-Jaramillo LE, Lechuga-Hernández S, et al. Omalizumab in the treatment of moderate to severe persistent asthma in the context of allergic and non-allergic asthma. Med Int Méx 2015;31:693-700.

  8. Pillai P, Chan Y-C, Wu S-Y, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Resp J 2016;48:1593-1601.

  9. Menzella F, Piro R, Facciolongo N, et al. Long-term benefits of omalizumab in patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011;7:9.

  10. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med Feb 1989;320(5):271- 277.

  11. Humbert M, Menz G, Ying S, et al. The Immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than differences. Immunology Today 1999;20:528-533.

  12. Humbert M, et al. High affinity IgE receptor bearing cells in bronchial biopsies from atopic and non-atopic asthma. Am J Respir Crit Care Med Jun 1996;153(6):1931-1937.

  13. Ying S, et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and non-atopic asthma. J Allergy Clin Immunol Jan 2007;119(1):213-218.

  14. Mouthuy J, Detry B, Sohy C, Pirson F, Pilette C. Presence in sputum of functional dust mite specific IgE antibodies in intrinsic asthma. Am J Respir Crit Care Med 2011 Jul 15;184(2):206-214.

  15. Navines-Ferrer A, Serrano-Candelas E, Molina Molina GJ, Martin M. IgE-related chronic diseases and anti-IgE based treatments. Hindawi Publising Corporation. J Immunol Res 2016:1-12. http://dx-doi.org/10-1155/2016/8163803.

  16. Herrera J. Use of omalizumab In Mexican patients with a diagnosis of moderate to severe non-atopic asthma: ATS journals in American Thoracic Society 2018 International Conference. Thematic Poster Session- San Diego Convention Center.

  17. Herrera García JC, et al. Use of omalizumab as treatment in patients with moderate and severe non-atopic asthma and associated with asthma- COPD overlap syndrome (ACOS) in asthma diagnosis and management. IntechOpen, DOI: 10.5772/intechopen.73904. July 4th 2018.

  18. Gaga M, Zervas E, Humbert M. Targeting immunoglobulin E in non-atopic asthma: crossing the red line? Eur Resp J 2016;48:1538-1540. DOI: 10.1183/13993003.01797-2016.

  19. Herrera J, et al. Successful use of omalizumab as a patient treatment with chronic rhinosinusitis, nasal polyps and severe asthma. In: National Congress of Pneumology: 17- 21 April 2017. Puebla, Puebla City.

  20. Garcia G, Magnan A, Chiron R, et al. A proof of concept, randomized, controlled trial of omalizumab in patients with severe, difficult to control, nonatopic asthma. Chest 2013;144:411-419.

  21. Lynch JP, Mazzone SB, Rogers MJ, Arikkatt JJ, Loh Z, Pritchard AL, Upham JW, Phipps S. The plasmacytoid dendritic cell: at the cross–roads in asthma. Eur Respir J 2014;43:264-275.

  22. Van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin prick test results. Chest 2011;139:190-193.

  23. Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Reg Homeostatic Agents 2013;27:45-53.

  24. De Llano LP, et al. Effects of omalizumab in non-atopic asthma: Results from a Spanish multicenter registry. J Asthma 2013;50:296-301.

  25. Herrera J, et al. Successful use of omalizumab in non atopic severe asthma In: National Congress of Pneumology. 17-21 April 2017. City of Puebla.

  26. Kutlu A, Demirer E, Ozturk S, Gunes A, Kartal O, Sezer O, Kartaloglu Z. Can anti-IgE treatment be used in non-atopic asthma patients: thoughts of a case about the role of IgE in asthma. Gülhane Tıp Dergisi 2014;56:46-44. Doi: 10.5455/ gullhane.11713




2020     |     www.medigraphic.com